Cooper Financial Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cooper Financial Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,518	Closed	-$561K	–	394
2025 Q1	$561K	Buy	4,518 +184	+4%	+$24K	0.07%	226
2024 Q4	$534K	Buy	4,334 +156	+4%	+$18.4K	0.06%	231
2024 Q3	$465K	Buy	4,178 +163	+4%	+$17.9K	0.06%	254
2024 Q2	$429K	Sell	4,015 -17	-0.4%	-$1.87K	0.06%	241
2024 Q1	$486K	Buy	4,032 +54	+1%	+$6.61K	0.08%	222
2023 Q4	$489K	Buy	3,978 +2	+0.1%	+$250	0.09%	207
2023 Q3	$515K	Buy	3,976 +201	+5%	+$26.8K	0.12%	186
2023 Q2	$468K	Sell	3,775 -46	-1%	-$6.19K	0.12%	203
2023 Q1	$559K	Buy	3,821 +1,939	+103%	+$287K	0.15%	155
2022 Q4	$300K	Buy	+1,882	New	+$276K	0.09%	224

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Cooper Financial Group's JAZZ Position: Q2 2025 in Review

Cooper Financial Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 4,518 shares — an estimated $561K sold.

Cooper Financial Group first reported a position in JAZZ in Q4 2022 and held it in 10 quarters. The position peaked at $561K in Q1 2025. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

Cooper Financial Group reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Cooper Financial Group sold 4,518 Jazz Pharmaceuticals shares in Q2 2025, an estimated $561K.
Cooper Financial Group first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 10 quarters.
Cooper Financial Group's Jazz Pharmaceuticals position peaked at $561K in Q1 2025.
501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Cooper Financial Group's 13F filing for Q2 2025, filed 18 Jul 2025.